"By Megan Brooks
Medscape Medical News
The US Food and Drug Administration (FDA) will require makers of prescription testosterone products to clarify the approved uses of these medications on the product label and add information"...
Overdose with NATRECOR® therapy has been reported and is primarily the result of either a miscalculated NATRECOR® dose or a mechanical error such as an infusion-pump malfunction or an infusion-pump programming error. The most frequently reported adverse event reported with NATRECOR® overdose is hypotension, which may be symptomatic and may persist for several hours. Asymptomatic hypotensive events may resolve with drug stoppage. In some cases hypotension may persist for several hours beyond discontinuation. In the event of an overdose, discontinue NATRECOR® and support blood pressure [see WARNINGS AND PRECAUTIONS].
NATRECOR® is contraindicated in patients with:
- Persistent systolic blood pressure < 100 mm Hg prior to therapy because of an increased risk of symptomatic hypotension [see WARNINGS AND PRECAUTIONS]
- Known hypersensitivity to any of its components [see WARNINGS AND PRECAUTIONS]
- Cardiogenic shock
Last reviewed on RxList: 9/4/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Natrecor Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.